WEITZMAN DEBORAH
SEC CIK 1942639 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CAH | Cardinal Health | CEO, Pharmaceutical Segment | 77.9K | — | $9.45M | 22 | 2022-12-01 | 2026-08-18 |
Most active insiders at CAH, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Hollar Jason M. | CEO | — | $29.38M |
| 2 | Alt Aaron E | CFO | — | $10.45M |
| 3 | Mason Stephen M | CEO, GMPD Segment | — | $8.27M |
| 4 | Mayer Jessica L | Chief Legal, Compliance Off | — | $6.95M |
| 5 | Greene Michelle D. | CIO | — | $3.37M |
| 6 | WEITZMAN DEBORAH | CEO, PSS Segment | — | $1.73M |
| 7 | Hall Patricia Hemingway | Dir | — | $918.9K |
| 8 | Scherer Mary C. | CAO | — | $546.5K |
| 9 | Pitteroff Valerie Christine | CHRO | — | — |
| 10 | Brennan Michelle | Dir | — | — |
Transactions 22
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-08-20 07:30 | 2026-08-18 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | S - Sale | $235.45 | -7,354 | 77.9K | -9% | -$1.73M |
| 2026-08-18 16:15 | 2026-08-15 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | A - Grant | $0.00 | +7,314 | 115.0K | +7% | $0 | |
| 2026-08-18 16:15 | 2026-08-15 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | F - Tax | $235.17 | -29.8K | 85.3K | -26% | -$7.00M | |
| 2026-08-06 06:04 | 2026-08-04 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | A - Grant | $0.00 | +54.8K | 107.7K | +104% | $0 | |
| 2025-12-02 | 2025-12-01 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | F - Tax | $212.26 | -551 | 52.9K | -1% | -$117.0K | |
| 2025-08-20 | 2025-08-20 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | S - Sale | $150.53 | -21.4K | 53.4K | -29% | -$3.22M | |
| 2025-08-19 | 2025-08-15 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | F - Tax | $150.22 | -24.1K | 74.8K | -24% | -$3.62M | |
| 2025-08-19 | 2025-08-15 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | A - Grant | $0.00 | +10.7K | 98.9K | +12% | $0 | |
| 2025-08-12 | 2025-08-12 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | A - Grant | $0.00 | +39.1K | 88.2K | +80% | $0 | |
| 2024-12-03 | 2024-12-02 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | F - Tax | $122.24 | -632 | 49.1K | -1% | -$77.3K | |
| M | 2024-08-19 | 2024-08-15+ | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | F - Tax | $106.66 | -12.3K | 49.8K | -20% | -$1.31M |
| 2024-08-19 | 2024-08-15 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | A - Grant | $0.00 | +13.5K | 52.1K | +35% | $0 | |
| 2024-08-14 | 2024-08-13 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, PSS Segment | A - Grant | $0.00 | +13.9K | 48.5K | +40% | $0 | |
| 2023-12-05 | 2023-12-01 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, Pharmaceutical Segment | F - Tax | $107.08 | -638 | 34.6K | -2% | -$68.3K | |
| DM | 2023-11-29 | 2023-11-27 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, Pharmaceutical Segment | M - OptEx | $74.10 | +27.6K | 50.2K | +123% | +$2.05M |
| D | 2023-11-29 | 2023-11-27 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, Pharmaceutical Segment | S - Sale+OE | $106.31 | -36.6K | 35.2K | -51% | -$3.90M |
| D | 2023-08-29 | 2023-08-28 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, Pharmaceutical Segment | S - Sale+OE | $89.81 | -6,712 | 44.2K | -13% | -$602.8K |
| D | 2023-08-29 | 2023-08-28 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, Pharmaceutical Segment | M - OptEx | $71.43 | +6,712 | 50.9K | +15% | +$479.4K |
| 2023-08-17 | 2023-08-16 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, Pharmaceutical Segment | A - Grant | $0.00 | +15.5K | 44.2K | +54% | $0 | |
| 2023-08-17 | 2023-08-15 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, Pharmaceutical Segment | F - Tax | $92.99 | -11.0K | 28.7K | -28% | -$1.02M | |
| 2023-08-08 | 2023-08-07 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, Pharmaceutical Segment | A - Grant | $0.00 | +12.8K | 39.7K | +47% | $0 | |
| 2022-12-05 | 2022-12-01 | CAH | Cardinal Health | WEITZMAN DEBORAH | CEO, Pharmaceutical Segment | F - Tax | $80.17 | -380 | 26.9K | -1% | -$30.5K |
Purchase Sale Sale after option exercise All abbreviations